Variegate porphyria (VP)is a low penetrance, autosomal dominant disorder that results from partial deficiency of protoporphyrinogen oxidase (PPOX) activity caused by mutation in the PPOX gene. The rare homozygous variant of VP is characterized by severe PPOX deficiency, onset of photosensitization by porphyrins in early childhood, skeletal abnormalities of the hand and, less constantly, short stature, mental retardation and convulsions. We have identified PPOX mutations on both alleles of five of the 11 unrelated patients with homozygous VP reported to date. Two patients were homoallelic for missense mutations (D349A and A433P), while three were heteroallelic. Functional analysis by prokaryotic expression showed that the D349A and A433P and one missense mutation in each of the three heteroallelic patients (G358R in two patients and A219KANA) preserved some PPOX activity (9.5-25% of Wild-type). Mutations on the other allele of the heteroallelic patients abolished or markedly decreased activity. There was no relation between genotype assessed by functional analysis and the presence or severity of non-cutaneous manifestations. The mutations were absent from 104 unrelated patients with autosomal dominant VP. Our findings define the molecular pathology of homozygous VP and suggest that mild PPOX mutations occur in the general population but have very low or no clinical penetrance in heterozygotes.
INTRODUCTION
Variegate porphyria (VP) is a low penetrance disorder of haem biosynthesis inherited as an autosomal dominant trait. Affected individuals have reduced activity of protoporphyrinogen oxidase (PPOX, EC 1.3.3.4) (1) . Patients present after puberty with skin lesions that are typical of bullous porphyrias or with acute neurovisceral crises, identical to those seen in other acute porphyrias, or with both together (1, 2) . The human PPOX gene contains one non-coding and 12 coding exons spread over 5 kb DNA (3) (4) (5) and is located on chromosome 1q23, the site to which VP maps (4) . In South Africa, 10 000-20 000 individuals of Afrikaans descent have inherited VP from a common ancestor and share a same mutation (R59W) in the PPOX gene (1, 6) . Elsewhere VP is less common (7) and a number of different mutations have been reported (8 and references therein).
Clinically silent (latent) VP is at least five times commoner than overt disease (1) and PPOX mutations are sufficiently frequent in European populations for rare cases of homozygosity for severe PPOX deficiency (homozygous VP) to occur outside consanguineous unions. The homozygous disease is characterized by the onset of skin lesions in early childhood, clinodactyly and occasionally other minor skeletal abnormalities of the hand; less constant clinical features include short stature, mental retardation, convulsions and nystagmus (9, 10) . Acute neurovisceral crises have not been observed. Since its first description in 1984 (9),10 patients from nine families have been reported (l0). Both parents of affected children have the biochemical features of latent VP but overt VP has been reported in only three families (6, 11, 12) .
Here we describe the characterization of PPOX mutations in five unrelated patients with homozygous VP, two of whom have not previously been reported, and explore the relationship between VP and its homozygous variant. Table 1 compares the clinical features of the five patients we studied. Mutations in the PPOX gene were identified by direct sequencing on both strands of cDNA (patients '1, 2 and 5) or genomic DNA (patients 3 and 4) after screening of all exons and their flanking sequences by denaturing gradient gel electrophoresis (DGGE) (exons 4 and 7-11 ) or heteroduplex analysis (exons 1-3,5,6,12 and 13). The presence of mutations in cDNA was confmned by sequencing or restriction enzyme *To whom correspondence should be addressed. Tel: +44 1222742799; Fax: +44 1222744905; Email: elder@cardiff.ac.uk digestion of genomic DNA. Mutations (505G~A, 1046A~C, 1072G~A and 1297G~C) that altered the amino acid sequence of PPOX were identified in patients 1-3 ( Table 2 ). The mutations in patient 2 have recently been independently identified (13) . Examination of genomic DNA from their parents showed that patients 2 and 3 were heteroallelic and homoallelic, respectively. DNA from the parents of patient 1 was not available but genomic DNA sequencing together with the presence of normal concentrations of mRNA indicated that he was homoallelic ( Table 2 ). Patient 4 was similarly shown to be heteroallelic for the same missense mutation (1072G~A) as patient 2 and for an 18 bp deletion (gtaggggaacccctggag) in intron 7 immediately adjacent to exon 7 that disrupted the splice donor site. cDNA from this patient was separated into two bands by agarose gel electrophoresis; sequencing of the shorter band showed deletion of exon 7. None of these five mutations decreased the concentration of mRNA for PPOX, as assessed by measurement of the PPOX:porphobilinogen (PBG) deaminase mRNA ratio in T lymphoblastoid cells (patients 1-4, mean ratio 0.91, range 0.73-0.99 versus mean 0.86, range 0.67-1.02 for five normal subjects).
RESULTS
In patient 5, mRNA for PPOX was decreased by 85% (PPOX:PBG dearninase mRNA ratio 0.13). Sequencing of cDNA showed a 12 bp (AAGGCCAACGCC) in-phase insertion after 657C that encodes KANA ( Table 2) ; sequence from the other allele was just detectable at a much reduced level. cDNA was subcloned into pGEMT and sequenced. Eight of 10 clones contained cDNA with the 12 bp insert as the only abnormality; the two remaining clones contained normal cDNA. Quantification of Table 1 . Homozygous variegate porphyria: clinical features of patients mRNA from each allele, using digestion of amplified cDNA with BstXI to distinguish them, showed that~90% of the mRNA produced by this patient contained the 12 bp insert. To identify the mutation responsible for .low expression of normal mRNA, amplified genomic DNA was directly sequenced from 400 bp DNA 5' of exon 1to immediately 3' of the polyadenylation signal, with the exception of central regions of all introns and the region of the insert in exon 7. This revealed only one difference from the normal PPOX sequence: a T~G transversion in intron 11 (1VS11-11T~G) that segregated independently of the KANA allele in her family. This transversion is situated in the polypyrimidine track of the exon 12 splice acceptor site (atcctctccgctcttctcagAACT). A mutation at this site is likely to impair splicing efficiency (14-16) with predominant formation of an unstable, abnormal mRNA species undetectable by our RT-PCR procedure. However, its functional significance remains uncertain in the absence of direct evidence that it impairs splicing.
Six of the mutations identified in our patients produced an abnormal pattern on DGGE or heteroduplex analysis ( Fig. 1) . None of these mutations was identified when 104 unrelated patients with VP were screened using these techniques or are included among mutations previously reported in this condition (6, 8) . The seventh mutation (1VSll-11T~G) was not present in any of28 VP patients in which this region ofthePPOX gene was sequenced or in 55 normal subjects screened by allele-specific oligonucleotide hybridization. In addition, none of our patients had parents or other relatives with clinically manifest VP. Figure 1 . Detection of PPOX mutations by DGGE (exons 7 and 10) and heteroduplex analysis (exons 6 and 13). For each exon, amplified DNA was either normal (+/+) or heterozygous (mutation/+).
DISCUSSION
The four missense and the KANA mutants were screened for PPOX activity by testing their ability to rescue the growth of the hemG (PPOX gene)-deficient SAS38X strain of Escherichia coli (17; Table 3 ). Four mutant PPOXs were able to rescue growth and their catalytic activities were compared with that of normal human PPOX expressed in the same strain. Relative activities ranged from 9.5 to 25% of normal (Table 3) . G l69E was also the only mutation of those we identified that altered a highly conserved residue that is unchanged in the human, mouse, Arabidopsis thaliana, Micrococcus xanthus, Bacillus subtilis and Saccharomyces cerevesiae genes (GenBank).
Prokaryotic expression of the mutations that complemented E.coli SAS38X showed that all our patients had a mutation that preserved some PPOX activity on at least one allele (Table 3) . Severe mutations that abolished PPOX activity (G I69E) or markedly decreased the concentration of normal mRNA (IVS7+1:18 bp deletion and JVSll-llT~G) werealways allelic to milder mutations (Tables 2 and 3 ) and may not support life when present on both alleles. Mutational analysis of the rare homozygous variants of the other autosomal "dominant hepatic porphyrias has shown a similar combination of mutations, with those that abolish activity always being allelic to a milder one (19) (20) (21) . Preservation of some activity is clearly essential to maintain the vital function of haem biosynthesis but the substantial loss of activity that can be tolerated, albeit at the cost of disease of variable severity, has been an unexpected fmding in all these disorders (19) (20) (21) (22) .
There are some discrepancies between PPOX activities measured in tissues and determined by prokaryotic expression · (Table 3 ). Accurate measurement of low PPOX activity in biological samples is made difficult by the relatively high and variable level of non-enzymatic auto-oxidation of protoporphyrinogen in the assay system. Human PPOX is a FAD-containing homodirner associated with the inner mitochondrial membrane (23) . At present, it is unclear how closely the activities of mutant PPOX homodirners expressed in prokaryotes reflect activities in human tissues. In addition to the technical difficulty of accurately measuring low tissue activities, PPOX activity in vivo may bemodified by its mitochondrial environment, by enzyme stability or by the formation of heterodimers, as would be predicted for patient 2 (G358R/Gl69E) in our study (Table 3) .
Comparison of the data in Tables I and 3 shows no correlation between the presence of severe non-cutaneous manifestations and the extent of residual PPOX activity. The most and least severely affected patients had the highest PPOX activities as determined by prokaryotic expression (Table 3 ). The mechanism whereby point mutations in the PPOX gene produce the variable, non-porphyric features of homozygous VP is unknown. Short stature and neurological defects are often present in homozygous variants of acute intermittent porphyria and hereditary coproporphyria (19) (20) (21) , suggesting that certain early stages of development may be critically dependent on haem biosynthesis. We have identified mutations on both alleles of five of the II unrelated patients with homozygous VP that have now been reported ( Table 2 ). Another two of these patients have been investigated previously: a South African patient was heteroallelic for the severe R59W founder mutation and a milder mutation (RI68C) (6) while a Finnish patient was heteroallelic for severe (Jl2T) and less severe (P256R) mutations (18) . Missense and KANA mutants were screened for PPOX activity by testing their ability to support the growth of an E.coli strain (SAS38X) that lacks PPOX activity (14) . Since E.coli requires only very low levels of PPOX to grow normally, even low activity mutants will complement SAS38X. Only mutant G 169E failed to sustain growth ( Table 3 ), indicating that it is non-functional. None of the mutations that we found was present in a large group of Western European patients with VP. In heteroallelic homozygous VP patients from South Africa and Finland, the more severe mutations cause overt VP in heterozygotes (6, 18) . Our failure to identify such VP patients probably reflects the greater allelic heterogeneity of the disease outside these countries where VP mutations have spread by founder effects. However, one of the milder mutations (G358R) was present in two homozygous VP patients, one from the Czech Republic and one from the UK, raising the possibility that this and perhaps other, relatively' mild mutations, while rarely if ever causing VP in heterozygotes, may not be so rare in the general population.
MATERIALS AND METHODS

Patients and families
Five unrelated patients (Table 1) , both parents of patients 2--4and the son of patient 5, were studied. The clinical and biochemical features of patients 1 (9), 2 (24) and 4 (9) have been reported. Patient 3, who developed severe skin lesions from the age of 8 . months, was found to have homozygous VP at the age of 7 years.
Patient 5 developed skin lesions at the age of 9 months. At the age of 20 years, short stature and hand deformities were noted in addition to skin lesions; the diagnosis of homozygous VP was established by porphyrin and PPOX assays. Now aged 33 years, she has had four normal pregnancies and has never had an attack of acute porphyria. A sample of 104 apparently unrelated patients (58 British and 46 French) with overt VP were also studied.
DNA analysis
Genomic DNA was extracted from whole blood by standard methods. cDNA for the entire coding sequence of PPOX was obtained in two overlapping fragments (exons 1-8 and 6-13) by RT-PCR from RNA isolated from T lymphoblastoid cells. Amplified genomic DNA was screened for the presence of mutations in the coding sequence and exon-intron boundaries by DGGE (exons 4 and 7-11), as previously described (25) but using PPOX-specific primers and conditions, or by heteroduplex analysis (exons 1-3, 5, 6, 12 and 13), using a modified polyacrylamide-based vinyl polymer gel (FMC Bioproducts) with electrophoresis for 10 h at 500 V. Double-stranded PCR products from cDNA or genomic cDNA were purified using the Qiaquick purification system or the Qiagen gel extraction kit before being cycle sequenced on both strands using fluorescent ddNTPs, AmpliTaqFS and an ABI 377 automated sequencer or sequenced manually as previously described (25) . Sequences were analysed by visual comparison with normal sequences. For patient 5, cDNA was subcloned into pGEMT before sequencing. Primer sequences and conditions for amplification, DGGE and heteroduplex analysis are available from the authors. Nucleotides are numbered from the first nucleotide of the translation initiation codon (equivalent to nt 278; GenBank accession no. D38537).
RNA analysis
RNA was extracted from T lymphoblastoid cells and reverse transcribed with M-MLV-RT. Fragments of mRNA for PPOX (331 bp, flanking exon 7) and porphobilinogen (PBG) deaminase (627 bp, exons 9-15) were amplified by PCR. Antisense primers were end-labelled with [y_32pJATP (3000 Ci/mmol), purified using the Qiagen nucleotide purification system and used at 10 nCi/pmol. Radiolabelled PCR products were purified by 5% polyacrylamide gel electrophoresis, visualized by autoradiography and quantified with a GS670 Bio-Rad Imaging Densitometer. Product formation was linear to 22 cycles; PPOX:PBG deaminase cDNA ratios were determined at 20 cycles.
Generation of recombinant mutant PPOXs
To generate the A433P, G358R and G169E mutants, the method of Deng and Nickoloff (26) was employed using the previously described human PPOX expression plasmid pHPPO-X (18). Specifically, the selection pIID1er in each case was 5' -CGCGTTGGTGCGGAATTCTCGGTAGTGGGAT-3', which mutated a unique EcoRV site in the vector to an EcoR! site.'For the A433P, G358R and G169E mutants, the mutagenesis primers were 5'-ACTAGAGTCACCTAGGCAATTCC-3', 5'-CCCTGAGCA-GGACAGGAGCCCCCCTGG-3' and 5'-CAGTCTCTGCCGT-GAAGTGTTTGCAGGC-3', respectively. To generate the 12 bp KANA insertion and the D349A mutation, the Quikchange mutagenesis method (Strategene) was used. For the KANA insertion and the D349A mutant, the sense primers 5'-GCACT-CATTCGCCAGGCCAAGGCCAACGCCTTGGCTGAGCG-CTGGAGC-3' and 5'-CCTGGGAATCGTGTATGCCTCA-GTTGCTTTCCC-3' and their complements were used according to the manufacturer's protocoL Mutated bases are shown in bold. All mutations were confirmed by DNA sequencing.
Complementation of PPOX-deficient E.coli
The E.coli strain SAS38X (17) , which lacks PPOX activity and is unable to grow without exogenously supplied haem, was used to study the in vivo functioning of the mutant PPOX enzymes. Fifty nanograms of each of the mutant enzyme-containing expression plasmids (A433P, G358R, G169E, the 12 bp KANA insertion and D349A) were electroporated individually into 50 J.lI aliquots of clectrocompetent SAS38X cells. The wild-type PPOX expression plasmid pHPPOX was used as a positive control and pGEM 3Z (Promega) was used as a negative control. After 1 h outgrowth, 100 J.lI each culture were plated onto LB + ampicillin plates and incubated at 37°C overnight. Each mutant enzyme was then evaluated for its ability to rescue growth of E.coli SAS38X in comparison with the wild-type enzyme.
Expression and characterization of mutant PPOX enzymes All mutant enzymes that were able to rescue growth of E.coli SAS38X were selected for further characterization. Cultures of each of the mutant PPOX-containing enzymes in this E.coli strain, as well as the wild-type human PPOX plasmid in this strain, were inoculated into.100 ml Circlegrow medium (Bio 101) supplemented with 100 ug/ml ampicillin and incubated at 37°C overnight. Cells were harvested and the pellets resuspended to 0.5 g wet wt/ml in 50 mM sodium phosphate, pH 7.4, 1% n-octyl-~-D-glucopyranoside, 10 ug/ml phenylmethylsulfonylfluoride. The resuspended cells were sonicated for 2 x 15 sand 50 JlI of each sample were assayed using the fluorescence assay described previously (23) . Under the conditions used, protoporphyrin formation was linear from 5 to at least 120% of mean wild-type PPOX activity. The protein content of each sample was determined by the BCA assay (Pierce).
